Role of Endoplasmic Reticulum Stress in the Pathophysiology of Type 2 Diabetes

Diabetes Mellitus, Type 2 Clinical Trial

— GLUCOSTRESS  

Official title:

Role of Endoplasmic Reticulum Stress in the Pathophysiology of Type 2 Diabetes

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02368704
• Other study ID #: GLUCOSTRESS P 08 11 22
• Status: Active, not recruiting
• Phase: N/A
• First received: February 15, 2015
• Last updated: April 15, 2016
• Start date: November 2012
• Est. completion date: November 2016

Study information

• Verified date: April 2016
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Ministry of HealthFrance: Direction Générale de la Santé
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to investigate whether Endoplasmic Reticulum (ER) stress pathway is activated in peripheral tissues (adipose tissue) in insulin resistant diabetic patients compared to healthy subjects normoglycemic matched for age and sex an to investigate whether ER stress pathway can be activated in response to insulin. Indeed, some preliminar on rates studies shows that ER stress pathway is activated by insulin in liver and adipose tissue showing that hyperinsulinemia might help trigger stress path ER.

For this, we propose a case control study of type 2 diabetic patients vs control subjects in which markers of ER stress will be evaluated from abdominal subcutaneous adipose tissue obtained before and after euglycemic hyperinsulinemic. We chose to consider adipose tissue subcutaneous rather than visceral adipose tissue for obvious reasons of lesser invasiveness.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 40
• Est. completion date: November 2016
• Est. primary completion date: November 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Specific criteria for diabetic patients:

• Having type 2 diabetes for at least 6 months

• HbA1c = 8%

• Treated by lifestyle and dietary rules associated or not to a hypoglycemic therapy (metformin and / or sulfamid) and / or insulin secretors dependent glucose as inhibitors of DPP4 (dipeptidyl peptidase-4): Vildagliptin, Sitagliptin, Saxagliptin

• No modification of hypoglycemic therapy and / or insulin secretors for at least 3 months

Specific criteria for control subjects:

• Nondiabetic subjects (fasting blood glucose <7.0 mmol / l without hypoglycemic treatment).

• The control subjects should be matched to patients for age (± 5 years), sex, and BMI (± 2 kg/m2).

Common criteria for patients and control subjects:

• Aged 18 to 60 years

• Body Mass Index between 25 and 35 kg/m2

• Accepting the constraints of the protocol and who signed the informed consent

• Systolic blood pressure < 160 mmHg, diastolic blood pressure < 90 mm Hg (with or without antihypertensive treatment)

• Resting heart rate between 55 and 100 beats/min.

• Normal laboratory tests or not clinically significant abnormality for NFS platelets, PT, aPTT, fibrinogen ALT, AST, GGT, Serum electrolytes, urea, creatinine, Uric acid Triglycerides, total cholesterol, HDL cholesterol

• HCG negative blood (for female subjects)

• Affiliated to the Social Security.

Exclusion Criteria:

• Current infections or recent infections (<10 days)

• Neoplastic disorders (with the exception of carcinoma in situ of the cervix or cutaneous epithelioma), haematological, cardiovascular, psychiatric, neurological

• Poisoning smoking (>10 cigarettes per day, what ever the duration of intoxication)

• Treatment with insulin or glitazones Pregnancy, Breastfeeding

• Body Mass Index > 35 kg/m2

• Any drug taken for less than 8 days without the inclusion of minor analgesics (aspirin, paracetamol), anti-hypertensive medications, oral hypoglycemic (metformin and sulphonylureas) and insulin secretors dependent glucose as inhibitors of DPP4 (dipeptidyl peptidase-4) and oral contraceptives.

Study Design

Observational Model: Case Control, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 2
• Endoplasmic Reticulum Stress

Intervention

Other:
• No intervention

Locations

Country	Name	City	State
France	Saint-Louis Hospital	Paris

Sponsors (1)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Show an increase in markers of ER stress in fasting patients with type 2 diabetes	Protein expression markers of ER stress pathway BiP / GRP 78, CHOP, ATF4 EDEM and XBP-1	2 days	No
Secondary	Assess whether insulin induces an increase in markers of ER stress	Insulin sensitivity	2 days	No
Secondary	Insulin secretion in response to glucose infusion		2 days	No
Secondary	Insulin secretion in response to arginine infusion		2 days	No
Secondary	Lipolysis on insulin		2 days	No